
Topic
Payer Policy
Medicare, commercial payer, PBM, and formulary-policy moves that shape launch curves and gross-to-net.

Pricing & Access· May 22, 2026 · 17 min read

Pipeline· May 22, 2026 · 13 min read
Patient-reported outcome endpoint translation from trial evidence to payer evidence
By Ran Chen#Clinical Evidence#Payer Policy#AMCP Dossier

Biosimilars· May 22, 2026 · 10 min read
Rituxan biosimilars: FDA status, interchangeability, payer coverage, and switching
By Ran Chen#Biosimilars#Oncology#Coverage Access

Specialty· May 22, 2026 · 11 min read
Site-of-care edits for IV and subcutaneous specialty drugs

Pricing & Access· May 22, 2026 · 12 min read
State PDAB launch-risk watchlist for market access teams
By Ran Chen#Drug Pricing#Market Access#Payer Policy

Specialty· May 22, 2026 · 11 min read
White bagging and brown bagging policies for infusion biologics
By Ran Chen#Specialty Pharmacy#Buy and Bill#Oncology

Biosimilars· May 21, 2026 · 8 min read
Eylea biosimilars: FDA status, interchangeability, launches, and payer coverage

Biosimilars· May 21, 2026 · 7 min read
Herceptin biosimilars: FDA status, payer coverage, coding, and switching
By Ran Chen#Biosimilars#Oncology#Coverage Access

Policy· May 21, 2026 · 8 min read
Medicare Part D redesign 2025-2026: IRA changes and access implications

Biosimilars· May 20, 2026 · 9 min read